Latest filing published 15 Mar 2022 for Aeglea BioTherapeutics, Inc., €142k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Jonathan Alspaugh: trading record in brief
Jonathan Alspaugh is a declared insider of Spyre Therapeutics, Inc. (finance chief), with filings sourced from SEC (Form 4). The record holds 5 filings, for trades running from 16 August 2021 to 11 March 2022.
On the market, this insider has only ever bought: 5 purchases, €530k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2022 alone, the filings show 1 purchase and no sales.
A typical purchase (the median) is worth €130k. On 2 out of 5 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
The newest entry dates from 15 March 2022: an open-market purchase of €142k, in Spyre Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Jonathan Alspaugh
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 75,000 shares@ US$2.0839.5% of flowCommon StockSEC:0001209191-22-018941:0Canonical exit: 9 Jun 2022 (T+90)
- 50,000 shares@ US$3.7245.7% of flowCommon StockSEC:0001209191-21-069349:0Canonical exit: 9 Mar 2022 (T+90)
- 9,780 shares@ US$6.367614.7% of flowCommon StockSEC:0001209191-21-052272:0Canonical exit: 14 Nov 2021 (T+90)
3 of 3 declarations
